We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
+31.74%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76.3M
AUM Growth
-$31.2M
Cap. Flow
-$46.8M
Cap. Flow %
-61.38%
Top 10 Hldgs %
87.57%
Holding
20
New
4
Increased
1
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$7.33M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$3.08M
3
FATE icon
Fate Therapeutics
FATE
+$1.38M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.33M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$1.14M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.5M
2
HUM icon
Humana
HUM
+$8.58M
3
CNC icon
Centene
CNC
+$6.36M
4
MRK icon
Merck
MRK
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$120B
$12.7M 16.6%
57,815
-7,034
-11% -$1.42M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$11.4B
$10.5M 13.74%
123,958
-12,042
-9% -$910K
BMY icon
3
Bristol-Myers Squibb
BMY
$126B
$8.53M 11.18%
132,832
-65,105
-33% -$3.73M
CI icon
4
Cigna
CI
$75.7B
$8.18M 10.72%
+40,000
New +$7.33M
ABBV icon
5
AbbVie
ABBV
$454B
$6.81M 8.93%
76,957
-55,043
-42% -$4.57M
IQV icon
6
IQVIA
IQV
$34.6B
$6.27M 8.22%
40,585
-17,401
-30% -$2.54M
ZTS icon
7
Zoetis
ZTS
$31.3B
$4.01M 5.26%
30,315
-60
-0.2% -$7.46K
SIEN
8
DELISTED
Sientra, Inc.
SIEN
$3.44M 4.51%
38,481
-19
-0% -$1.43K
TMO icon
9
Thermo Fisher Scientific
TMO
$213B
$3.23M 4.24%
9,959
-19,017
-66% -$5.77M
FATE icon
10
Fate Therapeutics
FATE
$294M
$3.17M 4.16%
161,977
+86,977
+116% +$1.38M
TNDM icon
11
Tandem Diabetes Care
TNDM
$1.16B
$2.98M 3.91%
+50,000
New +$3.08M
KRTX
12
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.96M 2.57%
+26,000
New +$1.14M
ASND icon
13
Ascendis Pharma A/S
ASND
$16.6B
$1.67M 2.19%
+12,000
New +$1.33M
HUM icon
14
Humana
HUM
$47.4B
$1.45M 1.89%
3,942
-27,058
-87% -$8.58M
ILMN icon
15
Illumina
ILMN
$29.8B
$1.43M 1.87%
4,430
-5,147
-54% -$1.56M
CDNA icon
16
CareDx
CDNA
$1.94B
– –
-184,855
Closed -$4.18M
CNC icon
17
Centene
CNC
$31.5B
– –
-147,000
Closed -$6.36M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
– –
-335,000
Closed -$2.69M
GILD icon
19
Gilead Sciences
GILD
$162B
– –
-197,916
Closed -$12.5M
MRK icon
20
Merck
MRK
$322B
– –
-77,552
Closed -$6.23M

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Copernicus Capital Management held 20 positions worth $76.3M, down 29% from $107M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Copernicus Capital Management withdrew a net $46.8M in Q4 2019, closing 5 positions and reducing 10 holdings. Its most notable exit was Gilead Sciences, an estimated $12.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Copernicus Capital Management opened a new position in Cigna worth $8.18M.

  • Copernicus Capital Management's largest Q4 2019 buy was Cigna: 40,000 shares worth $8.18M.
  • Copernicus Capital Management added most to Fate Therapeutics in Q4 2019, an estimated $1.38M increase.
  • Copernicus Capital Management's biggest Q4 2019 reduction was Humana, cutting an estimated $8.58M.
  • Copernicus Capital Management fully exited Gilead Sciences in Q4 2019, selling an estimated $12.5M.
  • Copernicus Capital Management's ten largest holdings make up 88% of its $76.3M portfolio in Q4 2019.
  • Copernicus Capital Management opened 4 new positions and closed 5 in Q4 2019.
  • Copernicus Capital Management's portfolio value fell 29% quarter-over-quarter to $76.3M.

Based on Copernicus Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.